secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001558370-24-007474
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios Therapeutics Q1 net loss $1.3M; Long-COVID study enrollment >50%
-----------------------------------------------------------------------

- Net loss $1.3M ($0.07/shr) vs $1.5M ($0.08/shr) in Q1 2023; cash $2.4M at March 31, 2024.
- R&D expenses $0.3M (down from $0.5M); G&A expenses $1.0M (down from $1.1M).
- BHC Long-COVID phase 2 trial (IMC-2) exceeded 50% enrollment; top-line data expected H2 2024.
- Preliminary safety shows IMC-2 well tolerated; no serious adverse events reported to date.
- Global patent for IMC-2 covering Long-COVID and Alzheimer's published; FM partner discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/0001558370-24-007474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024007474/viri-20240509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer